Thermo Fisher Q1 2026: Beats Estimates, Eyes Clario Ramp-Up

Thermo Fishers Q1 2026 results exceeded expectations with $11.01 billion revenue, up 6.2% YoY, and $5.44 EPS, beating estimates by 3.8%. Bioproduction and clinical research drove growth, with the $9 billion Clario acquisition contributing early. Despite beats, shares fell due to weak academic, government, and diagnostics sectors in the US and China. Guidance is cautious, focusing on bioproduction, Clario revenue, and new launches. Thermo is preparing for higher costs with pricing, cuts, and AI partnerships. Clarios ramp-up, spending laggard thaw, and inflations impact will determine Thermos performance in the bio game. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/471af9ce58be02ed